Metastatic Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Melanoma. A key objective of DelveInsights report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Metastatic Melanoma. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Melanoma. While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India. The research analysis also presents the global sales forecasts data till 2016.


Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope

• A snapshot of the global Market therapeutics scenario for Metastatic Melanoma.

• A review of the marketed products under prescription for Metastatic Melanoma, regulatory information and marketing status.

• Coverage of global patent coverage and detailed commentaries on the US patent challenges.

• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

• Product profiles for marketed products for Metastatic Melanoma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

• Coverage of API Manufacturers for Metastatic Melanoma drugs in the United States, Europe and Asian Regions with location details.

• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Metastatic Melanoma drugs.

• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Metastatic Melanoma drugs.

• Coverage of Metastatic Melanoma Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

• Key discontinued Marketed products.

• Global Sales Figure from 2012-2016.



Reasons to buy

• Evaluate the marketing status and exclusivity details of Metastatic Melanoma key products to exploit opportunities for generic drug development opportunities.

• Identify and understand important and diverse types of therapeutics under Phase III development for Metastatic Melanoma.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Metastatic Melanoma.

• API intelligence over marketed drugs for Metastatic Melanoma and gaining primary intelligence over active ingredients manufacturers across the globe.

• API intelligence over leading Phase III Pipeline drugs.

• Develop and design strategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

• Understanding the scope of the Phase III Drugs with nil regulatory filings.

• Understanding the chemical route of synthesis of approved drugs for Metastatic Melanoma.

• Uncovering opportunities in the rapidly growing US market.



Browse complete Report on:
http://www.aarkstore.com/pharmaceuticals-healthcare/98052/metastatic-melanoma-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2015



Table of Content

• Indication Overview
• Marketed Drugs
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing Status
• Marketed Details of Drugs by Patent Expiration Timeline
• Active Pharmaceutical Ingredient (API) Manufacturers Assessment
• API Manufacturers by United States Drug Master File (US DMF) Status
• API Manufacturers by US DMF Status (Drug Specific)
• API Manufacturers in Europe by Country
• API Manufacturers in India by State
• API Manufacturers in China by Province
• Marketed Details of Approved Drugs by Geography
• Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
• API Manufacturers by US DMF Status (Drug Specific)
• Drugs Market Data and Forecasted Sales Figure (2012-2016)
• Marketed Drugs for Metastatic Melanoma


Related Reports:

http://www.aarkstore.com/pharmaceuticals-healthcare/102512/pharmaceutical-industry-in-china

http://www.aarkstore.com/pharmaceuticals-healthcare/102376/healthcare-it-market-in-india-2015-2019

http://www.aarkstore.com/pharmaceuticals-healthcare/102527/annual-report-analysis-of-listed-amino-acid-companies-in-china

http://www.aarkstore.com/pharmaceuticals-healthcare/102581/vitamin-price-in-china



About Aarkstore Enterprise


Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.


Contact Details:

Aarkstore Enterprise
Phone: +91 998 729 5242
Email: [email protected]
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/